Before prescribing any GLP-1 medication, clinicians should take a thorough personal and family history specifically enquiring about thyroid cancer, particularly MTC, and any known hereditary endocrine syndromes
Adverse events observed with tirzepatide The adverse events observed in the clinical study program with tirzepatide are similar to those associated with therapy with GLP-1RA
Branded injectables can run over $500 a month without full coverage
Studies show that when patients stop GLP-1 medications, they typically regain much of the lost weight
You may be a candidate if you have a BMI of 27 or higher with a weight-related health condition (or 30 or higher without one), have tried diet and exercise without desired results, prefer a non-surgical option, and are committed to lifestyle changes
Alternatives If Vomiting Persists on GLP-1 Therapy When vomiting remains problematic despite dose adjustment and supportive measures, several alternative approaches merit consideration